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Essentials
• The phenotypes of different growth factor-independent 1B (GFI1B) variants are not established.
• GFI1B variants produce heterogeneous clinical phenotypes dependent on the site of mutation.
• Mutation of the first non-DNA-binding zinc-finger causes a mild platelet and clinical phenotype.
• GFI1B regulates the CD34 promoter; platelet CD34 expression is an indicator of GFI1B mutation.
Summary. Background: Mutation of the growth factorindependent 1B (GFI1B) fifth DNA-binding zinc-finger domain causes macrothrombocytopenia and a-granule deficiency leading to clinical bleeding. The phenotypes associated with GFI1B variants disrupting non-DNA-binding zinc-fingers remain uncharacterized. Objectives: To determine the functional and phenotypic consequences of GFI1B variants disrupting non-DNA-binding zinc-finger domains. Methods: The GFI1B C168F variant and a novel GFI1B c.2520 + 1_2520 + 8delGTGGGCAC splice variant were identified in four unrelated families. Phenotypic features, DNA-binding properties and transcriptional effects were determined and compared with those in individuals with a GFI1B H294 fs mutation of the fifth DNA-binding zinc-finger. Patient-specific induced pluripotent stem cell (iPSC)-derived megakaryocytes were generated to facilitate disease modeling. Results: The DNA-binding GFI1B variant C168F, which is predicted to disrupt the first non-DNA-binding zinc-finger domain, is associated with macrothrombocytopenia without a-granule deficiency or bleeding symptoms. A GFI1B splice variant, c.2520 + 1_2520 + 8delGTGGGCAC, which generates a short GFI1B isoform that lacks non-DNA-binding zinc-fingers 1 and 2, is associated with increased platelet CD34 expression only, without quantitative or morphologic platelet abnormalities. GFI1B represses the CD34 promoter, and this repression is attenuated by different GFI1B zinc-finger mutations, suggesting that deregulation of CD34 expression occurs at a direct transcriptional level. Patient-specific iPSC-derived megakaryocytes phenocopy these observations. Conclusions: Disruption of GFI1B non-DNA-binding zinc-finger 1 is associated with mild to moderate thrombocytopenia without a-granule deficiency or bleedingis a member of the GFI zinc (Zn)-finger transcriptional repressor family, and has a highly conserved N-terminal repressor domain called Snail/Gfi1 (SNAG), an intermediary domain, and six C-terminal C2H2 Zn-fingers [3, 4] . In murine cell lines, Zn-fingers 3, 4 and 5 are required for binding DNA in a sequence-specific manner, whereas Znfingers 1, 2 and 6 do not bind DNA, and their function remains unknown [3] [4] [5] .
The clinical significance of GFI1B was highlighted by initial reports [6] [7] [8] describing a significant bleeding disorder (platelet-type bleeding disorder 17 [OMIM 187900]) characterized by macrothrombocytopenia, a heterogeneous reduction in the number of platelet a-granules, and red blood cell abnormalities. The prevalence of this recently described disorder is not known, and it is limited to reports describing single-family pedigrees with mutations that appear to cluster in the GFI1B Zn-finger domains [9] [10] [11] [12] [13] .
By investigating thrombocytopenic families with a candidate gene panel, we identified two uncharacterized GFI1B variants that are predicted to disrupt the first and second non-DNA-binding Zn-fingers in four unrelated families. The first variant, GFI1B C168F, was present in individuals in three of these families, and is predicted to alter the conformation of the first non-DNA-binding Zn-finger domain of GFI1B. The second variant, a novel GFI1B splice variant, c.2520 + 1_2520 + 8delGTGGGCAC, was detected in family members of the fourth family, and is predicted to cause alternative splicing, with the formation of a short isoform lacking the first two Zn-finger domains. We compared the clinical, morphologic and functional features of these variants with those of a previously described GFI1B H294 fs mutant [6] of Zn-finger 5, and showed that the phenotype associated with different GFI1B variants is highly variable, suggesting complex regulation of thrombopoiesis by different Zn-finger domains of GFI1B.
To date, increased CD34 expression on platelets and megakaryocytes has been observed in different families with GFI1B mutations; however, the mechanism remains unknown [7, 8, 11, 13] . We demonstrate that CD34 is a transcriptional target of GFI1B, and show that all three variants reported (C168F, c.2520 + 1_2520 + 8delGTGGGCAC splice variant, and H294 fs) cause derepression at this promoter, suggesting that increased CD34 expression in GFI1B pedigrees is secondary to transcriptional dysregulation.
Materials and methods

Patients
Peripheral blood collection and skin punch biopsies were performed on individuals after written informed consent had been obtained. All research was approved by the Northern Sydney Human Research Ethics Committee, and was conducted in accordance with the Declaration of Helsinki (HREC/12/HAWKE/438).
Morphology and functional testing
Blood in EDTA tubes was used for automated full blood count analysis and peripheral blood film preparation (Sysmex XE-5000; Sysmex, Macquarie Park, NSW, Australia). Platelet diameters were measured with IM-AGE J (https://imagej.nih.gov/ij). Platelet pellets prepared from fresh blood collected in CTAD tubes were fixed with 2.5% glutaraldehyde in 0.1 mol L À1 cacodylate buffer, and stored at 4°C for transmission electron microscopy (TEM) with a Philips CM10 transmission electron microscope (FEI, Hillsboro, OR, USA). Resuspended cell pellets from induced pluripotent stem cell (iPSC)-derived megakaryocytes were cytocentrifuged (500 g) for 5 min onto glass slides, and hematoxylin and eosinstained preparations were imaged with a Nikon Eclipse 80i microscope (Nikon, Minato, Tokyo, Japan) at 9 40 magnification. Platelet function was assessed by light transmission aggregometry (LTA) with a standard baseline panel of agonists [14] (Chrono-Log Corporation, Havertown, PA, USA), and whole blood impedance aggregometry (WBIA) with a Multiplate analyzer (Roche Diagnostics International, Risch-Rotkreuz, Switzerland).
iPSC cultures between days 24 and 26 of culture and Meg01 cells between days 12 and 14 of culture were layered on a single-step albumin gradient (1.5-3.0% bovine serum albumin [BSA] ) and allowed to sediment for 1 h [15] . Megakaryocyte suspensions were then fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100 (Sigma, Castle Hill, NSW, Australia) in Hank's balanced salt solution (Life Technologies, Mulgrave, VIC, Australia) with 0.1 mM ethylene glycol tetraacetic acid (Sigma), and blocked with 0.5% BSA in phosphate-buffered saline. iPSC and Meg01 cell-derived megakaryocytes were then incubated with diluted (1:100) anti-von Willebrand factor (fluorescein isothiocyanate) ab8822 (Abcam, Cambridge, UK) and anti-CD34 (phycoerythrin) (BioLegend, San Diego, CA, USA), respectively. All cells were coated with Slow Fade Gold anti-fade reagent with 4 0 ,6-diamidino-2-phenylindole (Life Technologies). Imaging was performed with a Zeiss LSM Meta spectral confocal microscope (Carl Zeiss Pty Ltd, Macquarie Park, NSW, Australia) at 9 100 magnification, and iPSC a-granule numbers were determined with IMAGE J.
Flow cytometry
Platelet flow cytometry was used to measure surface expression of CD34, CD9, CD29, CD49b, CD36, CD41, CD61, CD42a, CD42b, and glycoprotein (GP) VI, with unlabeled antibodies (Beckman Coulter, Lane Cove West, NSW, Australia) and a secondary AF-488 goat anti-mouse antibody (Life Technologies). iPSC-derived megakaryocytes were labeled with allophycocyanin-conjugated mouse anti-human CD41a and PerCP-conjugated mouse anti-human CD34 mAbs (BD Biosciences, Franklin Lakes, NJ, USA). Flow cytometry was performed with the BD FACS Calibur or BD LSR Fortessa multichannel flow cytometer, and data were analyzed with BD CELL QUEST PRO and BD FACSDIVA, respectively (BD Biosciences). Platelet and iPSC-derived megakaryocyte CD34 mean fluorescence intensity measurements were normalized by the use of fluorochrome-conjugated isotype antibodies.
Western blotting
Total platelet proteins were separated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membranes were blocked and labeled overnight with mouse anti-CD62p (CTB201; BD Biosciences), anti-fibrinogen (PI1-115), anti-CD63 (BD Biosciences) and anti-CD34 (sc-19621; Santa Cruz Biotechnology, Dallas, TX, USA) mouse mAbs, and this was followed by incubation with horseradish peroxidase-conjugated goat anti-mouse antibody (Jackson ImmunoResearch, West Grove, PA, USA). Specific binding was detected by chemiluminescence, and densitometry measurements were performed with the Chemidoc XRS system with IMAGELAB (Bio-Rad, Gladesville, NSW, Australia).
Electrophoretic mobility shift assay (EMSA) and dual luciferase assay GFI1B-DNA interactions were analysed in vitro through the production of GFI1B proteins with the TNT T7-coupled Rabbit Reticulocyte Lysate System (Promega, Madison, WI, USA), and a 5 0 -biotin-labeled consensus GFI1B binding sequence probe with the Light Shift Chemiluminescent EMSA Kit (Thermo Fisher Scientific, Waltham, MA, USA). The wild-type (WT) oligonucleotide primer, 5 0 -GACACAAATAATCAGATTGAAA ATCAGGGAG-3 0 , was annealed with its complementary strand by incubation at 95°C followed by slow cooling to room temperature [16] . Protein lysate was incubated at room temperature with binding buffer and biotin-labeled double-stranded oligonucleotides. Samples were separated on a 5% acrylamide gel, in 0.5 9 Tris-borate-EDTA buffer, transferred to a nylon membrane for 30 min at 100 V, and cross-linked by the use of ultraviolet light. Biotinlabeled probes were visualized by chemiluminescence following incubation with peroxidase-conjugated streptavidin.
The CD34 and TUBB1 promoter sequences were analyzed, and revealed multiple GFI1B consensus binding motifs. Luciferase assays to determine the effects of GFI1B C168F, c.2520 + 1_2520 + 8delGTGGGCAC splice variant and H294 fs mutations at these promoters, as well as those of known GFI1B target promoters, GFI1B and MEIS1, were performed after transfection into the Meg01 cell line as previously described [6] (primers are listed in Table S1 ).
iPSC generation, cell lines, and megakaryocyte differentiation Patient-specific dermal fibroblasts were cultured, and transduced with the non-integrating Sendai virus delivering the four Yamanaka reprogramming factors (OCT3/4, Sox2, c-Myc, and Klf4) (Cytotune-iPS reprogramming kit; Life Technologies). Transduced cells were cultured on irradiated mouse embryonic fibroblasts (MEFs) (Merck Millipore, Bayswater, VIC, Australia) with basic fibroblast growth factor (Miltenyi Biotec, Macquarie Park, NSW, Australia). iPSC colonies staining for TRA1-60 were selected and maintained in an undifferentiated state on irradiated MEF plates. Patient-derived iPSCs were characterized by assessment of morphologic, molecular, karyotypic and functional features (representative images are shown in Figs S1 and S2). Megakaryocyte differentiation was performed with established methods [17] . Differentiating megakaryocytes were aspirated from culture on days 22-26 for microscopic and flow cytometric analysis.
The human megakaryoblastic cell line (Meg01) was transduced with lentivirus generated from 293T cells transfected with GFI1B variant vectors, and megakaryocyte differentiation was performed with established methods [18] .
Results
Heterozygous C168F mutation of the first Zn-finger domain of GFI1B causes thrombocytopenia without a-granule deficiency Massively parallel sequencing with a candidate gene panel identified multiple individuals in four unrelated families with variants in GFI1B (Fig. 1A-D) (Fig. 1E) . A missense mutation, GFI1B c.503G>T, segregated in an autosomal dominant manner with macrothrombocytopenia in three families of Indian origin ( Fig. 1A-C ). This single nucleotide change predicts a phenylalanine substitution for the cysteine at position 168 that directly interacts with the zinc ion essential for correct folding of the first Zn-finger domain [9, 19] . This substitution is predicted to disrupt the first Zn-finger with retention of normal folding of Znfingers 2-6. This variant has been independently reported in familial thrombocytopenia cohorts [9] .
Individuals with C168F showed mild to moderate macrothrombocytopenia with a mean platelet count of 111 9 10 9 L À1 and range of 76-143 9 10 9 L À1 ( Fig. 1F ; Table 1 ). Mean platelet diameters (MPDs) and MPD distribution widths (MPDDWs) measured by microscopy were larger for both the GFI1B C168F variant (n = 8) and the GFI1B H294 fs mutation of the fifth DNA-binding Znfinger [6] (n = 4) than in unaffected relatives (n = 6) (C168F MPD, P = 0.004; C168F MPDDW, P < 0.001; H294 fs MPD, P < 0.001; H294 fs MPDDW, P < 0.001) ( Table 1) . Bleeding symptoms were quantified with the ISTH-SSC bleeding assessment tool [20] ; individuals with C168F mutations did not report any consistent or significant bruising or bleeding symptoms (Table S2 ). There was no significant difference in median bleeding score between individuals with the C168F mutation (n = 10) and their unaffected relatives (n = 6) (0.5 [range 0-3] versus 0 [range 0-1]). However, median bleeding scores were lower in individuals with the C168F mutation than in those with the previously described symptomatic H294 fs mutation [6] (n = 6) (4 [range 0-8]). Moreover, there was a significant difference between the C168F and H294 fs groups when bleeding score cut-offs of 3 in males and 5 in females were used to discriminate a 'normal' from an 'abnormal' bleeding score (P = 0.015, Fisher's exact test) [21, 22] . Platelet function assessed by LTA (family A, I.1 and II.3; and family B, II.1; n = 3) (Fig. 1J ) and WBIA (all affected individuals in families A and B; n = 8) (Fig. 1K ) was normal in individuals with the C168F variant. Normal mepacrine uptake and release measured in two individuals (I.1 and II.3) from family A in conjunction with normal CD63 measured by western blotting in all six affected individuals from this family suggest normal platelet dense granules (Fig. 1L) . Individuals with the C168F mutation did not have any significant abnormalities of platelet surface GPs by flow cytometry. TEM was performed on platelets from two individuals (II.1 and II.3) in family A and from one individual (I.1) in family B. Platelets from these individuals showed normal numbers of a-granules (Fig. 1H) . To confirm that granules seen by microscopy were normal, the expression levels of the a-granule-related proteins Pselectin and fibrinogen were examined by western blotting and compared with those in healthy donors and those in individuals with the H294 fs mutation (Fig. 2) . No significant difference in the mean densitometry of P-selectin or fibrinogen was detected between C168F mutants (n = 6) and the normal control (n = 12) (P-selectin, 105% versus 100%, P = 0.631; fibrinogen, 105% versus 100%, P = 0.608). In contrast, substantial reductions in P-selectin and fibrinogen expression were observed in platelet lysates derived from H294 fs mutants (n = 8) as compared with those derived from C168F mutants (P < 0.001). This absence of a-granule deficiency in C168F platelets is consistent with the observed absence of a significant bleeding history in these individuals.
A splice variant of GFI1B causes expression of a short transcript
The fourth family ( Fig. 1 ; pedigree D and Fig. 1E ) had a pathogenic mutation of MYH9 c.C5797T (p.R1933X), as well as a GFI1B variant present within the exon-intron boundary, i.e. GFI1B c.2520 + 1_2520 + 8delGTGGG CAC. This deletion is predicted to remove the splice donor site following exon 4 without identifiable alternative sites. Abnormal splicing was predicted by in silico analysis by three independent bioinformatic tools (FRUIT-FLY.ORG, NETGENE2, and HUMAN SPLICING FINDER) [23] [24] [25] . GFI1B normally exists as a 330-residue protein, but a shorter transcript that excludes exon 4 that predicts a 284-residue protein without the first and second Zn-finger domains has been identified in leukemia cells [26] . Cloning of GFI1B from peripheral blood identified the presence of this short transcript in this pedigree. This short transcript was present in at least equivalent amounts to the long full-length GFI1B transcript.
Thrombocytopenia in affected members of pedigree D segregated with the pathogenic MYH9 R1933X mutation only ( Fig. 1D ; Table 2) . Surprisingly, individuals inheriting the GFI1B splice variant and wild-type MYH9 had normal platelet counts (mean, 228 9 10 9 L
À1
; range, 209-244 9 10 9 L À1 ). Moreover, platelets in these individuals appeared normogranular on peripheral blood films, and were indistinguishable from platelets from unaffected family members. MPDs and MPDDWs measured from these individuals were not increased as compared with one unaffected relative (DII.1) and the measurements from 20 unrelated controls (P = 0.17) (Table S3 ). All individuals with the GFI1B splice variant lacked abnormalities of platelet surface GP expression.
Increased platelet CD34 surface expression is a common feature of all GFI1B variants identified Increased CD34 expression in platelets has been reported to be associated with GFI1B mutations [7, 8, 10, 13] . To further explore this observation, flow cytometry was used to measure CD34 surface expression on platelets of individuals with the GFI1B mutations C168F (pedigrees A, B, and Fig. 1 . Platelet phenotype of the growth factor-independent 1B (GFI1B) C168F mutation and GFI1B splice mutation. (A- ND, not defined. The mean platelet volume was not recordable in eight of the 10 affected individuals with GFI1B C168F mutations and in seven of the nine individuals with MYH9 R1933X and/or GFI1B splice mutations, owing to interference caused by the observed population of large platelets that resulted in loss of the log normal platelet volume distribution on the automated analyzer.
C; n = 10) and H294 fs (previously reported pedigree [6] ; n = 2), and the GFI1B splice mutation (pedigree D; n = 7). For comparison, CD34 surface expression was measured on platelets of individuals with mutations in two other transcription factors that are important in megakaryopoiesis, FLI1 and RUNX1, of unaffected relatives, and of individuals with pathogenic MYH9 mutations. Platelet surface CD34 expression was increased in platelets with all GFI1B variants, but was not detected in platelets from unaffected relatives (n = 9) or from patients with FLI1 (n = 4), RUNX1 (n = 5) or MYH9 mutations (n = 6) (Fig. 3A,B) . To verify this observation, total CD34 protein in platelets was also measured by western blotting. CD34 protein levels were increased in platelet lysates from individuals with H294 fs (n = 8), C168F (n = 5) and GFI1B splice variants (n = 3) as compared with unaffected relatives (n = 9) (Fig. 3C,D) .
The GFI1B C168F variant and the GFI1B c.2520 + 1_2520 + 8delGTGGGCAC splice variant alter gene transcription GFI1B functions as a transcriptional repressor [4, 5, 27] . Luciferase assays were performed in Meg01 cells that express endogenous GFI1B to determine whether the C168F variant and c.2520 + 1_2520 + 8delGTGGGCAC splice variant alter transcription at target promoters. Transcriptional effects were analyzed at two known GFI1B target genes, GFI1B and MEIS1, as well as at CD34 and TUBB1, to determine whether aberrant transcriptional signaling was a determinant of the observed platelet changes and whether cytoskeletal dysregulation contributed to the hematologic phenotype. Transfection of WT transcript repressed transcription at GFI1B, TUBB1, MEIS1 and CD34 promoters as H294fs C168F donors Fig. 2 . a-Granule protein content is normal in C168F individuals. Platelet lysate protein expression as measured by mean densitometry for C168F individuals (n = 6), H294fs individuals (n = 8) and healthy donors (n = 12) demonstrates significant reductions in fibrinogen (A) and Pselectin (B) in the H294fs group only (*P < 0.001). Actin is shown as the protein loading control. compared with the empty vector, consistent with previous reports of GFI1B functioning as a transcriptional repressor [3] [4] [5] 27, 28] . The C168F and GFI1B splice variants caused mild reversal of transcriptional repression as compared with WT GFI1B at the MEIS1, TUBB1 and CD34 promoters, as indicated by the relative increase in luciferase signal ( Fig. 4 ; Table S4 ). However, the degrees of derepression caused by both C168F and GFI1B splice variants at these promoters were significantly lower than that caused by the H294 fs mutation (P < 0.001). Taken together, the increased CD34 surface expression determined by flow cytometry and the increased total CD34 expression determined by western blotting are consistent with the transcriptional changes observed at the CD34 promoter (Fig. 4) , demonstrating derepression by GFI1B C168F, splice site and H294 fs mutations, and suggesting that CD34 is a GFI1B target.
Mutation of the first Zn-finger domain of GFI1B does not abolish the ability to bind DNA Zn-finger domains 3-5 of GFI1B are considered to directly interact with DNA [4] . To determine the effects of mutation of the first Zn-finger domain (C168F) and the fifth Zn-finger domain (H294 fs) of GFI1B on DNA binding at the GFI1B promoter, recombinant proteins of mutant and WT GFI1B of appropriate molecular mass were produced, and their ability to bind of platelet CD34 expression is demonstrated for the growth factor-independent 1B (GFI1B) C168F (blue), GFI1B H294fs (red) and GFI1B splice mutations (green) as compared with platelets from an individual with a pathogenic MYH9 mutation (purple). (B) Platelet CD34 surface expression in individuals with H294 fs, C168F and GFI1B splice mutations, unaffected relatives, and individuals with recognized mutations of FLI1, RUNX1, and MYH9 (*P < 0.005, **P < 0.001). Box plots represent the 25th and 75th quartiles. (C, D) Platelet lysate CD34 expression as measured by western blotting for wild-type controls (n = 9) and individuals with H294 fs (n = 8), C168F (n = 5) and GFI1B splice mutations (n = 3). CD34 expression is significantly increased by all GFI1B variants relative to controls (P < 0.001, P < 0.005 and P < 0.05, respectively). b-Actin is shown as the protein loading control. FITC, fluorescein isothiocyanate; NS, not significant.
to the consensus DNA-binding sequence for GFI1B was then measured by EMSA (Fig. 5) . WT protein and the C168F mutant bound DNA, but GFI1B binding was abrogated by the H294 fs mutation, suggesting that the thrombocytopenia observed in these three families with C168F variants was not directly related to a failure of the mutant form of GFI1B to bind to DNA consensus sites.
Patient-specific iPSC-derived megakaryocytes and transduced Meg01 cell phenocopy abnormalities are observed in patients with different GFI1B mutations
To explore the laboratory phenotypic observations made in patient blood samples, megakaryocytes differentiated from patient-specific iPSCs, and Meg01 cell lines, were analyzed for CD34 expression and a-granule numbers. iPSCs were generated from skin fibroblasts from one individual in pedigree A with the C168F mutation (Fig. 1, AII.3 ) and from one individual with the H294 fs mutation. iPSCs from a related, unaffected individual were used as a control for all experiments. To account for clonal variation between iPSCs [29] , two iPSC clones from each individual were selected for megakaryocyte differentiation. CD34 expression determined by flow cytometry was significantly increased in C168F and H294 fs iPSCderived megakaryocytes as compared with control megakaryocytes (Fig. 6B ). An increased total CD34 level was also observed in differentiated Meg01 cells stably transduced with the C168 or H294 fs transcript (Fig. 6C) . Confocal microscopy was performed to assess iPSCderived megakaryocyte a-granules. C168F megakaryocytes (n = 8) appeared normogranular relative to controls (n = 8) (mean a-granules per platelet: 46.9 versus The growth factor-independent 1B (GFI1B) C168F and GFI1B c.2520 + 1_2520 + 8delGTGGGCAC variants alter gene transcription. Meg01 cells were transfected with an empty vector control, wild-type (WT) transcript, or mutant GFI1B transcript, and transcriptional activity was measured at the GFI1B, TUBB1, MEIS1 or CD34 promoter. WT and mutant transcripts alter transcription as compared with empty vector (*P < 0.05, **P < 0.01). As compared with WT transcript, C168F and GFI1B splice mutant transcripts derepress transcription to a lesser degree than H294 fs transcript (#P < 0.01). The data are expressed as fold change in luciferase activity, and represent mean AE standard error of the mean.
GFI1B DNA probe GFI1B WT GFI1B C168F GFI1B H294fs 100x non-bio primer 41.5, P = 0.66), whereas H294 fs megakaryocytes (n = 8) showed variable decreases in the numbers of a-granules, with some megakaryocytes containing numerous a-granules and other megakaryocytes being markedly hypogranular (mean a-granules per platelet, H294 fs versus C168F: 21.5 versus 46.9, P = 0.05) (Fig. 6D,E) . The CD34 expression and a-granule pattern of iPSC-derived megakaryocytes and Meg01-transduced cell lines recapitulated the changes observed in patients with mutations involving Zn-fingers 1 and 5, causing increased CD34 expression, but only a mutation involving Zn-finger 5 was associated with an a-granule defect.
Discussion
Increasing numbers of GFI1B variants have been described since the original descriptions of this bleeding disorder [6] [7] [8] , with accurate characterization of these variants being important for clinical prediction of bleeding risk. For the three variants presented in this study, the clinical phenotypes ranged from the previously reported thrombocytopenic disorder with a-granule deficiency and significant bleeding (H294 fs), to individuals who had a normal platelet count and no clinical bleeding (GFI1B splice mutation), and an intermediate phenotype (C168F) with macrothrombocytopenia but no a-granule deficiency or bleeding symptomatology. This pattern suggests segregation of the platelet phenotype according to the type of variant, and which Zn-finger domain bears the GFI1B variant.
Both the C168F mutation and the H294 fs mutation cause mild to moderate thrombocytopenia; however, bleeding symptoms were distinctly lacking in individuals with C168F variants. Platelets in these individuals appeared normogranular on the peripheral blood film. This observation was confirmed by TEM imaging studies, and validated by western blots examining platelet a-granule contents with P-selectin and fibrinogen as surrogate markers of a-granule number. These proteins had normal expression in individuals with the C168F mutation, but reduced expression in those with the H294 fs mutation. Moreover, confocal imaging of iPSC-derived megakaryocytes generated from individuals with C168F mutations showed normal numbers of a-granules relative to control megakaryocytes. a-Granules concentrate large polypeptides that are important for primary and secondary hemostasis. The significant reduction in a-granule number coupled with cytoskeletal changes is postulated to be a major factor contributing to bleeding in individuals with H294 fs mutations [6] , and may therefore explain the absence of bleeding history reported by individuals with C168F mutations. Importantly, the allele frequency of the C168F variant reported in the Exome Aggregation Consortium sequencing data is 0.0006011, and is highest in the 'South Asian' population (0.004385) [30] . Consistent with these frequency data, all three families with the C168F variant reported here are of Indian descent, suggesting that the C168F variant may represent a proportion of asymptomatic-mildly thrombocytopenicmacrothrombocytopenic individuals from this region.
GFI1B DNA binding is predicted to occur via Zn-finger domains 3, 4, and 5, and is necessary for the transcriptional repression that is mediated by the N-terminal SNAG domain [3] [4] [5] 31] . Previous modeling and our EMSA data suggest that Zn-fingers 1, 2 and 6 are dispensable for DNA binding, and their exact function remains unknown [4] . The physiologic importance of the first and second Zn-finger domains of GFI1B in normal megakaryopoiesis and platelet production has been suggested by studies of the long (L) and short (S) alternative splice products of GFI1B. The S-isoform lacks exon 4, resulting in loss of the first two Zn-fingers that are present in the L-isoform [9, 32] . Mutations that prevent formation of the L-isoform impair megakaryocyte differentiation and platelet production [13, 33] . Similarly, we have shown that an altered conformation of the first Zn-finger caused by the GFI1B C168F mutation is associated with thrombocytopenia that occurs despite preserved GFI1B-DNA binding.
The GFI1B c.2520 + 1_2520 + 8delGTGGGCAC splice deletion is characterized in this study by increased CD34 expression only, and not thrombocytopenia, a-granule defects, and bleeding symptoms. This mutation causes alternative splicing with formation of the GFI1B S-isoform, which has been shown to be important in erythropoiesis [33] . Studies in CD34 + cells and zebrafish have Fig. 6 . Growth factor-independent 1B (GFI1B) C168F and H294 fs induced pluripotent stem cell (iPSC)-derived and differentiated Meg01 cells recapitulate changes seen in patient platelet samples. (A) Representative images of hematoxylin and eosin-stained megakaryocytes at day 22 of differentiation (9 40 whereas H294 fs caused a marked increase in cytosolic CD34 expression, consistent with the western blotting of platelet lysates in Fig. 3 . Nuclei are stained with 4 0 ,6-diamidino-2-phenylindole (DAPI) (blue). (D) Representative confocal images (9 100 magnification) of iPSCderived megakaryocytes immunostained for the a-granule protein von Willebrand factor (VWF) (green). Nuclei are stained with DAPI (blue). Scale bars: 10 lm. (E) Frequency histograms of the number of a-granules per megakaryocyte as measured by confocal microscopy in H294fs (n = 8) (top) and H168F (n = 8) (bottom) iPSC-derived megakaryocytes.
shown that overexpression of the S-isoform affects neither megakaryocyte number nor maturation, suggesting that the L-isoform and S-isoform of GFI1B are functionally distinct [9] . Notably, the L-isoform is retained in individuals with the GFI1B splice mutation described in our study. The requirement of the L-isoform for platelet production is emphasized by a recent report of a homozygous GFI1B c.551InsG variant causing alternative splicing with markedly reduced formation of this L-isoform [13] . Homozygous offspring of asymptomatic heterozygotes in this kindred experienced a severe bleeding defect associated with thrombocytopenia with reduced a-granule numbers.
Considered together, the phenotypic differences identified for the C168F mutation, GFI1B splice variant and H294 fs mutation suggest that these differences are not limited to the GFI1B domain that is disrupted by the mutation, but are also dependent on the functional consequences of the variant. It is possible, but has yet to be demonstrated, that the GFI1B splice variant causes haploinsufficiency that is insufficient to alter the absolute number of platelets or red blood cells. This is consistent with mouse studies in which homozygous deletion of Gfi1b causes a combined failure of erythroid and megakaryocytic development in mice embryos, whereas haploinsufficiency with one functional copy of WT Gfi1b lacks a hematologic phenotype [34] . In the case of the C168F missense variant, our data suggest that the resulting phenotype may be attributable to conformational change induced by the variant of the first Zn-finger that does not affect DNA binding, but that may disrupt interactions with other protein complexes, interfere with the DNA-binding Zn-fingers 3, 4, and 5, or cause disruption of specific protein-DNA interactions [4, [35] [36] [37] .
The increased CD34 expression associated with these three different GFI1B variants suggests that CD34 is a transcriptional target of GFI1B. The dual luciferase reporter data demonstrate direct repression at the CD34 promoter by WT GFI1B. Furthermore, we found that both Zn-finger 1 and Zn-finger 5 mutations reduced repression at the CD34 promoter, and propose that altered transcription at the CD34 promoter underscores the functional basis of increased CD34 expression associated with GFI1B mutations. Atypical expression of CD34 by platelets has also been reported in two families with RUNX1 mutations [38] . We did not, however, detect increased platelet CD34 expression in five individuals (three of whom have developed acute myeloid or acute lymphoblastic leukemia) from two unrelated families with RUNX1 mutations, suggesting that increased CD34 expression secondary to a RUNX1 mutation may be variant-dependent. In addition, increased CD34 expression was not detected in individuals from a previously reported family [39] with a pathogenic FLI1 mutation, suggesting that increased CD34 expression is not a universal marker of transcription factor mutations associated with platelet disorders.
In conclusion, the C168F and GFI1B c.2520 + 1_2520 + 8delGTGGGCAC variants are predicted to disrupt non-DNA-binding Zn-fingers of GFI1B, and are associated with milder clinical and platelet phenotypes that are distinct from that of the H294 fs mutation of the fifth DNA-binding Zn-finger. Transcriptional dysregulation caused by the C168F mutation is independent of DNA binding, suggesting a separate function for this domain in the regulation of platelet production. Finally, we have shown that the CD34 promoter is a direct transcriptional target of GFI1B and that repression of CD34 transcription is attenuated with mutations of GFI1B, resulting in increased total platelet and surface platelet expression of CD34. In all three variants described here, increased CD34 expression is independent of the site of mutation, and appears to be a general marker of perturbed GFI1B function. As increased CD34 expression has also been reported with other GFI1B variants [7, 8, 11, 13] , CD34 protein expression may serve as a screening assay for the presence of GFI1B mutations in the setting of familial platelet disorders.
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